10-QPeriod: Q1 FY2004

IDEXX LABORATORIES INC /DE Quarterly Report for Q1 Ended Mar 31, 2004

Filed May 10, 2004For Securities:IDXX

Summary

IDEXX Laboratories, Inc. reported a solid first quarter for 2004, demonstrating robust revenue growth driven primarily by its Companion Animal Group (CAG), which represents the largest segment of the business. Total revenue increased by 22% year-over-year, with CAG revenue up 25%. This growth was fueled by strong performance in rapid assays, instrument consumables, and laboratory services. The company also saw improved gross profit margins, expanding by 300 basis points to 50% of revenue, indicating effective cost management and favorable product mix. Net income grew significantly, reflecting the strong top-line performance and operational efficiencies. The company continues to invest in R&D and strategic acquisitions, as evidenced by the acquisition of a veterinary reference laboratory in Ohio. While facing competitive markets and regulatory landscapes, IDEXX appears to be executing well on its growth strategies, positioning it for continued expansion.

Key Highlights

  • 1Total revenue for the first quarter of 2004 increased by 22% to $133.4 million compared to $109.2 million in the prior year's quarter.
  • 2The Companion Animal Group (CAG) segment, the largest contributor, saw revenue growth of 25% to $109.8 million.
  • 3Gross profit increased by 30% to $67.0 million, with gross profit margin expanding to 50% from 47% in the prior year, showcasing improved operational efficiency.
  • 4Net income saw a substantial increase of 48% to $17.8 million, or $0.49 per diluted share, up from $12.1 million, or $0.34 per diluted share, in the same period last year.
  • 5The company repurchased $22.4 million of its common stock during the quarter under its ongoing share repurchase program.
  • 6IDEXX completed an acquisition of a veterinary reference laboratory in Ohio in February 2004 for $6.8 million, integrating it into its Companion Animal Group.
  • 7Operating expenses increased by 23% to $41.7 million, but as a percentage of revenue, they remained stable at 31%, indicating effective cost control relative to revenue growth.

Frequently Asked Questions

Revenue growth was primarily driven by the Companion Animal Group (CAG), with significant increases in sales of rapid assay products, instrument consumables, and laboratory services. The Water and Food Diagnostics Group segments also contributed positively to overall revenue growth.

Profitability improved significantly. Gross profit increased by 30% and the gross profit margin expanded to 50% from 47%. Net income grew by 48% to $17.8 million, indicating strong operational performance and effective cost management.

The company expects future growth to depend on new product development, market expansion, and strategic acquisitions. Key risks identified include intense market competition, rapid technological changes, regulatory compliance, potential shifts in veterinary medical practices, reliance on proprietary technologies, supply chain dependencies, manufacturing complexities for biologic products, dependence on distributor purchasing patterns, and international market risks.

During the first quarter of 2004, IDEXX acquired a veterinary reference laboratory in Ohio for $6.8 million, which was integrated into its Companion Animal Group. The company also continued to invest in research and development to support new product development efforts.